Strategic use of lamivudine in the management of chronic hepatitis B

Antiviral Research

Volumn 100, Issue 2, 2013, Pages 435-438

  Soriano, Vincent ^a   McMahon, Brian ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b ALASKA NATIVE MEDICAL CENTER   (United States)

Author keywords

Developing regions; Drug resistance; Entecavir; Hepatitis B; Lamivudine; Tenofovir

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA; TENOFOVIR; ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; BONE DEMINERALIZATION; DRUG COST; DRUG INDICATION; DRUG SAFETY; DRUG USE; FANCONI RENOTUBULAR SYNDROME; FRACTURE; HEPATITIS B; HUMAN; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; LIVER FIBROSIS; MIXED INFECTION; MONOTHERAPY; OSTEOPENIA; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; VIRUS REPLICATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; ARTICLE; DEVELOPING REGIONS; DRUG RESISTANCE; ECONOMICS;

HEPATITIS B VIRUS;

DEVELOPING REGIONS; DRUG RESISTANCE; ENTECAVIR; HEPATITIS B; LAMIVUDINE; TENOFOVIR;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE;

EID: 84885332743     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.08.026     Document Type: Note

References (49)

1. Z. Abbas, and A. Siddiqui Management of hepatitis B in developing countries World J. Hepatol. 3 2011 292 299
2. D. Baxa, A. Thekdi, A. Golembieski, P. Krishnan, O. Sharif, A. Kizy, L. Shetron-Rama, J. Jovanovich, B. Chappell, A. Snow-Lampart, K. Borroto-Esoda, and S. Gordon Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States J. Hepatol. 58 2013 212 216
3. R. Bedimo, N. Maalouf, S. Zhang, H. Drechsler, and P. Tebas Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents AIDS 26 2012 825 831
4. M. Chang, R. Chien, C. Yeh, and Y. Liaw Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B J. Hepatol. 43 2005 72 77
5. T. Chang, R. Gish, R. De Man, A. Gadano, J. Sollano, Y. Chao, A. Lok, K. Han, Z. Goodman, J. Zhu, A. Cross, D. de Hertogh, R. Wilber, R. Colonno, and D. Apellan A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N. Engl. J. Med. 354 2006 1011 1020
6. T. Chang, Y. Liaw, S. Wu, E. Schiff, K. Han, C. Lai, R. Safadi, S. Lee, W. Halota, Z. Goodman, Y. Chi, H. Zhang, R. Hindes, U. Iloeje, S. Beebe, and B. Kreter Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B Hepatology 52 2010 886 893
7. C. Chen, H. Yang, J. Su, C. Jen, S. You, S. Lu, G. Huang, and U. Iloeje Risk of hepatocellular carcinoma across biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73
8. L. Chen, Q. Zhang, D.-M. Yu, M. Wan, and X. Zhang Early changes of HBV quasispecies during lamivudine treatment and the correlation with antiviral efficacy J. Hepatol. 50 2009 895 905
9. M. Del Palacio, S. Romero, and J.L. Casado Proximal tubular renal dysfunction or damage in HIV-infected patients AIDS Rev. 14 2012 179 187
10. J. Dienstag, R. Goldin, E.J. Heathcote, H. Hann, M. Woessner, S. Stephenson, S. Gardner, D. Grey, and E. Schiff Histological outcome during long-term lamivudine therapy Gastroenterology 124 2003 105 117
11. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B J. Hepatol. 50 2009 227 242
12. P. Easterbrook, A. Sands, and H. Harmanci Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings Semin. Liver Dis. 32 2012 147 157
13. S. Fujisaki, Y. Yokomaku, T. Shiino, T. Koibuchi, J. Hattori, S. Ibe, Y. Iwatani, A. Iwamoto, T. Shirasaka, M. Hamaguchi, and W. Sugiura Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan J. Clin. Microbiol. 49 2011 1017 1024
14. J. Fung, C.-L. Lai, J. Yuen, C. Cheng, R. Wu, D. Wong, W. Seto, I. Hung, and M. Yuen Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable HBV DNA: outcome at 2 years Hepatology 53 2011 1148 1153
15. E. Gane The roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B Hepatol. Int. 2 2008 304 307
16. R. Gish, J.-D. Jia, S. Locarnini, and F. Zoulim Selection of chronic hepatitis B therapy with high barrier to resistance Lancet Infect. Dis. 12 2012 341 354
17. D. Havlir, and D. Richman Viral dynamics of HIV: implications for drug development and therapeutic strategies Ann. Intern. Med. 124 1996 984 994
18. U. Iloeje, H. Yang, J. Su, C. Jen, S. You, and C. Chen Predicting cirrhosis risk based on the level of circulating hepatitis B virus viral load Gastroenterology 130 2006 678 686
19. R. Jayakumar, Y. Kumar-Joshi, and S. Singh Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir, and combination of lamivudine and adefovir J. Lab. Physic. 4 2012 10 16
20. A. Karras, M. Lafaurie, A. Furco, A. Bourgarit, D. Droz, D. Sereni, C. Legendre, F. Martinez, and J.M. Molina Tenofovir-related nephrotoxicity in HIV-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus Clin. Infect. Dis. 36 2003 1070 1073
21. E. Keeffe, S. Zeuzem, and R. Koff Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B Clin. Gastroenterol. Hepatol. 5 2007 890 897
22. C. Kim, S. Um, Y. Seo, J. Jung, J. Kim, H. Yim, B. Keum, Y. Kim, Y. Jeen, H. Lee, H. Chun, C. Kim, and H. Ryu Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleoside analogue antiviral agents J. Gastroenterol. Hepatol. 27 2012 1589 1595
23. Kitrinos K, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, Miller M. 2013. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. In press.
24. S. Koklu, Y. Tuna, M. Gulsen, M. Demir, A. Köksal, M. Koçkar, C. Aygün, S. Coban, K. Ozdil, H. Ataseven, E. Akin, T. Pürnak, I. Yüksel, H. Ataseven, M. Ibiş, B. Yildirim, I. Nadir, M. Küçükazman, E. Akbal, O. Yüksel, O. Başar, E. Alkan, and O. Baykal Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis Clin. Gastroenterol. Hepatol. 11 2013 88 94
25. P. Labarga, P. Barreiro, L. Martin-Carbonero, S. Rodriguez-Novoa, C. Solera, J. Medrano, P. Rivas, M. Albalater, F. Blanco, V. Moreno, E. Vispo, and V. Soriano Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir AIDS 23 2009 689 696
26. C. Lai, R. Chien, N. Leung, T. Chang, R. Guan, D. Tai, K. Ng, P. Wu, J. Dent, J. Barber, S. Stephenson, and D. Gray A one-year trial of lamivudine for chronic hepatitis B N. Engl. J. Med. 339 1998 61 68
27. C. Lange, J. Bojunga, W. Hofmann, K. Wunder, U. Mihm, S. Zeuzem, and C. Sarrazin Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function Hepatology 50 2009 2001 2006
28. Y. Liaw, J. Sung, W. Chow, G. Farrell, C. Lee, H. Yuen, T. Tanwandee, Q. Tao, K. Shue, O. Keene, J. Dixon, D. Gray, and J. Sabbat Lamivudine for patients with chronic hepatitis B and advanced liver fibrosis N. Engl. J. Med. 351 2004 1521 1531
29. F. Liu, L. Chen, D.-M. Yu, L. Deng, R. Chen, Y. Jiang, L. Chen, S. Huang, J. Yu, Q. Gong, and X. Zhang Evolutionary patterns of HBV quasispecies under different selective pressures: correlation with antiviral efficacy Gut 60 2011 1269 1277
30. A. Lok, and B. McMahon Chronic hepatitis B Hepatology 45 2007 507 539
31. A. Lok, C. Lai, N. Leung, G. Yao, Z. Cui, E. Schiff, J. Dienstag, E.J. Heathcote, N. Little, D. Griffiths, S. Gardner, and M. Castiglia Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714 1722
32. A. Lok, J. Ward, R. Perrillo, B. McMahon, and T. Liang Reactivation of hepatitis B in patients receiving immunosuppressive therapy: potentially fatal yet preventable Ann. Intern. Med. 156 2012 743 745
33. Y. Lui, K. Tsoi, V. Wong, J. Kao, J. Hou, E. Teo, R. Mohamed, T. Piratvisuth, K. Han, U. Mihm, G. Wong, and H. Chan Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as teh rescue therapy Antivir. Ther. 15 2010 145 155
34. P. Marcellin, E. Heathcote, M. Buti, E. Gane, R. de Man, Z. Krastev, G. Germanidis, S. Lee, R. Flisiak, K. Kaita, M. Manns, I. Kotzev, K. Tchernev, P. Buggisch, F. Weilert, O. Kurdas, M.L. Shiffman, H. Trinh, M. Washington, J. Sorbel, J. Anderson, A. Snow-Lampart, E. Mondou, J. Quinn, and F. Rousseau Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N. Engl. J. Med. 359 2008 2442 2455
35. T. Miyauchi, T. Kanda, M. Shinozaki, H. Kamezaki, S. Wu, S. Nakamoto, K. Kato, M. Arai, S. Mikami, N. Sugiura, M. Kimura, N. Goto, F. Imazeki, and O. Yokosuka Efficacy of lamivudine or entecavir against virological rebound after achieving HBV-DNA negativity in chronic hepatitis B patients Int. J. Med. Sci. 10 2013 647 652
36. A. Ono, F. Suzuki, Y. Kawamura, H. Sezaki, T. Hosaka, N. Akuta, M. Kobayashi, Y. Suzuki, S. Saitou, Y. Arase, K. Ikeda, M. Kobayashi, S. Watahiki, R. Mineta, and H. Kumada Long-term continuous entecavir therapy in nucleos(t)ide naïve chronic hepatitis B patients J. Hepatol. 57 2012 508 514
37. B. Rifkin, and M. Perazella Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure Am. J. Med. 117 2004 282 284
38. M. Rizzetto, N. Tassopoulos, R. Goldin, R. Esteban, T. Santantonio, E.J. Heathcote, M. Lagget, N. Taak, M. Woessner, and S. Gardner Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B J. Hepatol. 42 2005 173 179
39. A. Snow-Lampart, B. Chappell, and M. Curtis No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus Hepatology 53 2011 763 773
40. V. Soriano, A. Perelson, and F. Zoulim Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J. Antimicrob. Chemother. 62 2008 1 4
41. P. Tan, M. Aung, Y. Dan, Y. Lee, K. Lim, H. Low, G. Lee, M. Thwin, C. Soon, and S. Lim Liver disease progression and virological response: entecavir rescue still possible in the setting of rtM204I lamivudine-resistant mutation Gut 62 2013 801 802
42. D. Tenney Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight of entecavir resistance studies Antivir. Ther. 15 2010 529 535
43. D. Tenney, R. Rose, C. Baldick, K. Pokornowski, B. Eggers, J. Fang, M. Wichroski, D. Xu, J. Yang, R. Wilber, and R. Colonno Long-term monitoring shows HBV resistance to entecavir in nucleoside-naïve patients is rarely through 5 years of therapy Hepatology 49 2009 1503 1514
44. P. Tuma, J.A. Pineda, P. Labarga, F. Vidal, C. Rodriguez, E. Poveda, J. Santos, J. Gonzalez, P. Sobrino, C. Tural, and V. Soriano HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain Antivir. Ther. 16 2011 585 589
45. A. Vallet-Pichard, V. Mallet, B. Nalpas, V. Verkarre, A. Nalpas, V. Dhalluin-Venier, H. Fontaine, and S. Pol FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest Hepatology 46 2007 32 36
46. Z. Xu, Y. Liu, T. Xu, L. Chen, L. Si, Y. Wang, X. Ren, Y. Zhong, J. Zhao, and D. Xu Acute hepatitis B infection associated with drug-resistant hepatitis B virus J. Clin. Virol. 48 2010 270 274
47. S. Zeuzem, E. Gane, Y. Liaw, S. Lim, A. Di Bisceglie, M. Buti, A. Chutaputti, J. Rasenack, J. Hou, C. O'Brien, T. Nguyen, J. Jia, T. Poynard, B. Belanger, W. Bao, and N. Naoumov Baseline characteristics and early on-treatment response predcit teh outcomes of 2 years of telbivudine treatment of chronic hepatitis B J. Hepatol. 51 2009 11 20
48. Q. Zheng, J. Jiang, J. Chen, Y. Zhu, Y. Liu, and Y. Chen Serum HBV DNA level at week 24 as a proper predictor for the effect of 2-year lamivudine treatment Chin. Med. J. 124 2011 1257 1260
49. F. Zoulim, and S. Locarnini Management of treatment failure in chronic hepatitis B J. Hepatol. 56 Suppl. 1 2012 112 122